Diffuse Large B Cell Lymphoma: Updates on Diagnosis and Treatments

  • 7,938

    Total downloads

  • 27k

    Total views and downloads

Articles

CLINICAL TRIAL

Published on 26 Feb 2024

CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma

  • Lourdes Hontecillas-Prieto
  • Daniel J. García-Domínguez
  • Natalia Palazón-Carrión
  • Alejandro Martín García-Sancho
  • Esteban Nogales-Fernández
  • Carlos Jiménez-Cortegana
  • María L. Sánchez-León
  • Silvia Silva-Romeiro
  • Rocío Flores-Campos
  • 20 more
  • Luis de la Cruz-Merino
CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma
doi 10.3389/fimmu.2024.1293931
  • 1,638 views
  • 2 citations

Impact

  • 27kTopic views
  • 18kArticle views
  • 7,938Article downloads
View impact